Genzyme in the UK

Company Info

Myozyme® (alglucosidase alfa) Shortlisted for Prix Galien Real World Evidence Award

Date: 30 June, 2016

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced that Myozyme® (alglucosidase alfa) has been shortlisted for a Prix Galien medal within the “Real World Evidence” category which recognises excellence in the generation, collection and application of observational data to demonstrate health outcomes, real-world patients benefits or socio-economic gains.

“It is a great honour to be shortlisted for this prestigious Prix Galien Award,” said Peter Kuiper, General Manager UK & Ireland at Sanofi Genzyme. “Pompe disease is a rare genetic, progressive, debilitating and often fatal disorder and owing to the small numbers of patients with the disease there was limited understanding of its natural history or the full impact of its treatment. Sanofi Genzyme established a Pompe Registry in 2004 and analyses from the Registry have broadened our understanding of the disease and are helping clinicians to diagnose and treat patients sooner, which can have a positive impact on survival rates.”

The Prix Galien, set up in France by pharmacist Roland Mehl and since expanded across Europe, Canada and the U.S., were established to recognise and promote significant advances in pharmaceutical research. They honour medical research, pharmacology and pharmaceutical innovation, celebrating outstanding efforts to improve the human condition through the development of novel, high-value medicines.

The Real World Evidence Award, new for 2016, is open to medicines that have either won or received a commendation at previous UK Prix Galien Awards.

Winners will be honored at the 2016 UK Prix Galien Awards Ceremony on 21 September, 2016, at the House of Commons, London. For further information on The Galien Foundation Prix Galien Awards, please visit: http://prixgalien.co.uk/.

-  Ends -

About Myozyme® (alglucosidase alfa)

Myozyme® (alglucosidase alfa) is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase (GAA) deficiency).

Myozyme® (alglucosidase alfa) was approved as an orphan medicinal product in the EU and U.S. in 2006 for the treatment of adult and paediatric patients with Pompe disease.

For full prescribing information about Myozyme®, the Summary of Product Characteristics can be found here: http://www.medicines.org.uk/emc/medicine/19030

About Pompe Disease

Pompe disease is a progressive, debilitating and often fatal neuromuscular disease caused by a genetic deficiency or dysfunction of the lysosomal enzyme acid alpha-glucosidase (GAA) affecting an estimated 50,000 people worldwide. This enzymatic defect results in the accumulation of glycogen primarily in muscle tissues that leads to muscle weakness, loss of respiratory function, and often premature death. Without treatment, when symptoms occur in infancy, babies typically die within the first year of life. When symptoms occur in childhood or adulthood, patients often lose their ability to walk and require wheelchairs to assist with mobility and experience difficulty breathing as well as mechanical ventilation to breathe.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Genzyme® and Myozyme® are registered trademark of Genzyme Corporation. Sanofi® is a registered trademark of Sanofi. All rights reserved.

GZUK.MYOZ.16.06.0532  
Date of preparation: June 2016

Highlight

  • Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right

    Sanofi-aventis and Genzyme Corporation announced that they have entered into a definitive agreement under which sanofi-aventis is to acquire Genzyme for $74.00 per share in cash, or approximately $20.1 billion. Read the full corporate press release.

Contact Info:

Genzyme Therapeutics Ltd
4620 Kingsgate
Cascade Way
Oxford Business Park South
Oxford
OX4 2SU
Tel: +01865 405200
Fax: +01865 774172
Email

Contact Info:

Genzyme Ltd, Haverhill Operations
12 Rookwood Way
Haverhill
Suffolk
CB9 8PU
Tel: +01440 703522
Fax: +01440 716269

'